secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001193125-26-202504
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Apellis amends executive severance plan to accelerate vesting upon change of control in Biogen merger
--------------------------------------------------------------------------------

- Compensation committee approved amendment to Executive Separation Benefits Plan on April 28, 2026, in connection with Biogen merger.
- Unvested converted options and RSU awards will accelerate upon termination without cause or for good reason after closing.
- 'Good Reason' definition modified for C-Level Officers to include changes in scope due to becoming a subsidiary.
- Amendment effective upon closing of the merger; applies to each named executive officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312526202504/0001193125-26-202504-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312526202504/d147392d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-202504

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer